Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 2/20 | 0.57 |
| ▸ | CA2 | P00918 | 2/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA7 | P43166 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.57 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.57 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.57 |
| ▸ | PDE4A | P27815 | 1/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.56 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.55 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.55 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL600676 | 1.00 | PDPK1 (0.61) | PDPK1CA1CA2CA12CA7 | |
| SCHEMBL1988494 | 1.00 | PDPK1 (0.61) | PDPK1CA1CA2CA12CA7 | |
| SCHEMBL2466144 | 1.00 | PDPK1 (0.61) | PDPK1CA1CA2CA12CA7 | |
| SCHEMBL607818 | 0.90 | HTT (0.68) | HTTTAS1R3TAS1R1TAS1R2ALDH1A1 | |
| SCHEMBL31301105 | 0.90 | HTT (0.68) | HTTTAS1R3TAS1R1TAS1R2ALDH1A1 | |
| SCHEMBL8340594 | 0.90 | HTT (0.68) | HTTTAS1R3TAS1R1TAS1R2ALDH1A1 | |
| SCHEMBL6445345 | 0.90 | HTT (0.68) | HTTTAS1R3TAS1R1TAS1R2ALDH1A1 | |
| SCHEMBL11147902 | 0.89 | MTNR1A (0.50) | PDPK1CA1CA2CA12CA7 | |
| SCHEMBL19658435 | 0.89 | EPHX1 (0.63) | HTTTAS1R3TAS1R1TAS1R2ALDH1A1 | |
| SCHEMBL3421659 | 0.84 | HTT (0.60) | PDPK1CA1CA2PDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0192492-B1 | PEPTIDES CONTAINING AN ALIPHATIC-AROMATIC KETONE SIDE CHAIN | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1992-01-02 | — | — | EP | claimed |
| EP-3356345-B1 | HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS | MAX PLANCK GESELLSCHAFT (DE) | 2023-11-08 | — | — | EP | disclosed |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-05-11 | — | — | US | disclosed |
| US-20210108245-A1 | Enantioselective Biocatalytic Preparation of 4-Cyano-Substituted 1-Aminoindane and Ozanimod | PHARMAZELL GMBH (DE) | 2021-04-15 | — | — | US | disclosed |
| US-10457669-B2 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-10-29 | — | — | US | disclosed |
| WO-2019197571-A1 | ENANTIOSELECTIVE BIOCATALYTIC PREPARATION OF 4-CYANO-SUBSTITUTED 1-AMINOINDANE AND OZANIMOD | UNIVERSITÄT BIELEFELD (DE) | 2019-10-17 | — | — | WO | disclosed |
| EP-3553179-A1 | ENANTIOSELECTIVE BIOCATALYTIC PREPARATION OF 4-CYANO-SUBSTITUTED 1-AMINOINDANE AND OZANIMOD | Universität Bielefeld (DE) | 2019-10-16 | — | — | EP | disclosed |
| US-20190047990-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-02-14 | — | — | US | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-29 | — | — | US | disclosed |
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-29 | — | — | US | disclosed |
| WO-1999059721-A1 | CATALYTIC ASYMMETRIC HYDROGENATION, HYDROFORMYLATION, AND HYDROVINYLATION VIA TRANSITION METAL CATALYSTS WITH PHOSPHINES AND PHOSPHITES | THE PENN STATE RESEARCH FOUNDATION (US) | 1999-11-25 | — | — | WO | disclosed |
| WO-1998005651-A1 | NOVEL GLUTAMATE RECEPTOR ANTAGONISTS: FUSED CYCLOALKYL QUINOXALINEDIONES | WARNER-LAMBERT COMPANY (US) | 1998-02-12 | — | — | WO | disclosed |
| EP-0192492-B1 | PEPTIDES CONTAINING AN ALIPHATIC-AROMATIC KETONE SIDE CHAIN | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1992-01-02 | — | — | EP | disclosed |
| US-4692447-A | HYPOTENSIVE, VASODILATOR, ANTITHROMBOTIC, ANTIAGGREGANT, CYTOPROTECTIVE | BOEHRINGER BIOCHEMIA ROBIN, S.P.A. (IT) | 1987-09-08 | — | — | US | disclosed |
| US-4677193-A | GONADOTROPIN-RELEASING FACTOR ANALOGS | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1987-06-30 | — | — | US | disclosed |
| EP-0192492-A2 | Peptides containing an aliphatic-aromatic ketone side chain | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1986-08-27 | — | — | EP | disclosed |
| EP-0169443-A2 | Tricyclic dihydropyridazinones and pharmaceutical compositions contaning them | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1986-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | PDPK1 239/4885CA1 3792/4885CA2 1845/4885 |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | SPR, QDPR, SRR | PDPK1 4354/4885CA1 3605/4885CA2 3943/4885 |
| US-20190047990-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | PDPK1 239/4885CA1 3792/4885CA2 1845/4885 |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | PDPK1 911/4885CA1 3353/4885CA2 3978/4885 |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | PDPK1 250/4885CA1 3915/4885CA2 1947/4885 |
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | GPR3, FFAR3, LPAR3 | PDPK1 4069/4885CA1 2436/4885CA2 1056/4885 |
| US-10457669-B2 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | PDPK1 239/4885CA1 3792/4885CA2 1845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.